#ES­MO20: Trodelvy da­ta show that Gilead­'s $21B buy­out may have been worth the big pre­mi­um

Gilead CEO Dan O’Day has been on a shop­ping spree. And while some an­a­lysts gawked at the biotech’s re­cent $21 bil­lion Im­munomedics buy­out, new da­ta re­leased at vir­tu­al ES­MO 2020 sug­gest the ac­qui­si­tion may have been worth the hefty price.

The deal, an­nounced last week­end, will give Cal­i­for­nia-based Gilead $GILD Trodelvy, which was re­cent­ly ap­proved for metasta­t­ic triple-neg­a­tive breast can­cer (mTNBC).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.